Bismuth-Based Quadruple Therapy as First-Line Treatment for Clarithromycin-Resistant Helicobacter pylori Infection: A Prospective Randomized Comparison of 7- and 14-Day Treatment Regimens
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Bismuth-based quadruple therapy (BQT) is a treatment option for clarithromycin- resistant Helicobacter pylori (HP) infection. The aim of this study was to compare the efficacy of 7-day BQT with that of 14-day BQT as first-line treatment for clarithromycin-resistant HP infection. Methods: A total of 162 treatment-naïve patients with peptic ulcer disease and clarithromycinresistant HP infection confirmed by real-time polymerase chain reaction (RT-PCR) were enrolled. The enrolled patients were prospectively randomized to receive BQT for either 7 or 14 days of treatment. Eradication of HP infection was assessed using a 13C-urea breath test. Eradication and adverse event rates of the two groups were assessed. Results: The overall eradication rates in the intention-to-treat (ITT) and per-protocol (PP) analyses were 83.0% (95% confidence interval [CI], 77.2% to 88.9%; 132/159) and 89.8% (95% CI, 84.9% to 94.7%; 132/147), respectively. The eradication rates in the ITT analysis were 79.0% (64/81) in the 7-day group and 87.2% (68/78) in the 14-day group (p=0.170). The eradication rates in the PP analysis were 86.5% (64/74) in the 7-day group and 93.2% (68/73) in the 14-day group (p=0.182). Clinically significant adverse events occurred in 18.2% of patients. There was no statistically significant difference in the rates of individual or all adverse events between the two groups. Conclusions: Both 7-day and 14-day BQT were effective and safe as first-line therapy for HP infections identified as resistant to clarithromycin by RT-PCR. For clarithromycin-resistant HP infections, 7-day BQT may be sufficient as first-line therapy.
Abstract
Background/Aims: Bismuth-based quadruple therapy (BQT) is a treatment option for clarithromycin- resistant Helicobacter pylori (HP) infection. The aim of this study was to compare the efficacy of 7-day BQT with that of 14-day BQT as first-line treatment for clarithromycin-resistant HP infection. Methods: A total of 162 treatment-naïve patients with peptic ulcer disease and clarithromycinresistant HP infection confirmed by real-time polymerase chain reaction (RT-PCR) were enrolled. The enrolled patients were prospectively randomized to receive BQT for either 7 or 14 days of treatment. Eradication of HP infection was assessed using a 13C-urea breath test. Eradication and adverse event rates of the two groups were assessed. Results: The overall eradication rates in the intention-to-treat (ITT) and per-protocol (PP) analyses were 83.0% (95% confidence interval [CI], 77.2% to 88.9%; 132/159) and 89.8% (95% CI, 84.9% to 94.7%; 132/147), respectively. The eradication rates in the ITT analysis were 79.0% (64/81) in the 7-day group and 87.2% (68/78) in the 14-day group (p=0.170). The eradication rates in the PP analysis were 86.5% (64/74) in the 7-day group and 93.2% (68/73) in the 14-day group (p=0.182). Clinically significant adverse events occurred in 18.2% of patients. There was no statistically significant difference in the rates of individual or all adverse events between the two groups. Conclusions: Both 7-day and 14-day BQT were effective and safe as first-line therapy for HP infections identified as resistant to clarithromycin by RT-PCR. For clarithromycin-resistant HP infections, 7-day BQT may be sufficient as first-line therapy.
참고문헌 (26)
- Malfertheiner P, "Management of Helicobacter pylori infection : the Maastricht V", Florence Consensus Report, 2017, pp.66, 6~30
- Cerqueira L, "Validation of a fluorescence in situ hybridization method using peptide nucleic acid probes for detection of Helicobacter pylori clarithromycin resistance in gastric biopsy specimens", J Clin Microbiol, 51, pp.1887~1893 (2013)
- Jung DH, "Peptide nucleic acid probebased analysis as a new detection method for clarithromycin resistance in Helicobacter pylori", Gut Liver, 12, pp.641~647 (2018)
- Noh JH, "Real-time polymerase chain reaction for the detection of Helicobacter pylori and clarithromycin resistance", Gut Liver, 17, pp.375~381 (2023)
- Cho JH, "Cost-effectiveness of a tailored Helicobacter pylori eradication strategy based on the presence of a 23S ribosomal RNA point mutation that causes clarithromycin resistance in Korean patients", J Gastroenterol Hepatol, 34, pp.700~706 (2019)
- Gweon TG, "An economic modeling study of Helicobacter pylori eradication : comparison of dual priming oligonucleotide-based multiplex polymerase chain reaction and empirical treatment", Gut Liver, 12, pp.648~654 (2018)
- Lee HJ, "Eradication of Helicobacter pylori according to 23S ribosomal RNA point mutations associated with clarithromycin resistance", J Infect Dis, 208, pp.1123~1130 (2013)
- Liu Q, "Efficacy of real-time PCR-based detection of Helicobacter pylori infection and genotypic resistance-guided quadruple therapy as the first-line treatment for functional dyspepsia with Helicobacter pylori infection", Eur J Gastroenterol Hepatol, 27, pp.221~225 (2015)
- Chey WD, "ACG clinical guideline : treatment of Helicobacter pylori infection", Am J Gastroenterol, 112, pp.212~239 (2017)
- Jung HK, "Evidence based guidelines for the treatment of Helicobacter pylori infection in Korea 2020", Korean J Intern Med, 36, pp.807~838 (2021)
- Chinese Society of Gastroenterology, "Fourth Chinese National Consensus Report on the management of Helicobacter pylori infection", J Dig Dis, 14, pp.211~221 (2013)
- Kim SG, "Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition", J Gastroenterol Hepatol, 29, pp.1371~1386 (2014)
- Chung JW, "Second-line Helicobacter pylori eradication : a randomized comparison of 1-week or 2-week bismuth-containing quadruple therapy", Helicobacter, 16, pp.289~294 (2011)
- Lee BH, "Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection : effect of treatment duration and antibiotic resistance on the eradication rate in Korea", Helicobacter, 15, pp.38~45 (2010)
- Yoon JH, "Comparison of the eradication rate between 1-and 2-week bismuth-containing quadruple rescue therapies for Helicobacter pylori eradication", Gut Liver, 6, pp.434~439 (2012)
- Shin K, "Second-line bismuthcontaining quadruple therapy for Helicobacter pylori infection : a 12-year study of annual eradication rates", J Clin Med, 10, pp.3273~ (2021)
- Kim TH, "Comparison of 7-and 14-day eradication therapy for Helicobacter pylori with first-and second-line regimen : randomized clinical trial", J Korean Med Sci, 35, pp.e33~ (2020)
- Kim SY, "Types of 23S ribosomal RNA point mutations and therapeutic outcomes for Helicobacter pylori", Gut Liver, 15, pp.528~536 (2021)
- Kang JM, "Second-line treatment for Helicobacter pylori infection : 10-day moxifloxacin-based triple therapy versus 2-week quadruple therapy", Helicobacter, 12, pp.623~628 (2007)
- Moon SG, "Seven days of bismuth-based quadruple therapy is as effective for the first-line treatment of clarithromycin-resistant confirmed Helicobacter pylori infection as 14 days of bismuthbased quadruple therapy", J Clin Med, 11, pp.4440~ (2022)
- Thung I, "Review article : the global emergence of Helicobacter pylori antibiotic resistance", Aliment Pharmacol Ther, 43, pp.514~533 (2016)
- López-Góngora S, "Systematic review and meta-analysis : susceptibility-guided versus empirical antibiotic treatment for Helicobacter pylori infection", J Antimicrob Chemother, 70, pp.2447~2455 (2015)
- Malfertheiner P, "Management of Helicobacter pylori infection : the Maastricht IV", Florence Consensus Report, 2012, pp.61, 646~664
- Na SY, "Effective eradication regimen and duration according to the clarithromycin susceptibility of Helicobacter pylori determined using dual priming oligonucleotide-based multiplex polymerase chain reaction", Gut Liver, 17, pp.722~730 (2023)
- Chen D, "Phenotypic and molecular antimicrobial susceptibility of Helicobacter pylori", Antimicrob Agents Chemother, 61, pp.e02530~16 (2017)
- Lee JH, "Nationwide antibiotic resistance mapping of Helicobacter pylori in Korea : a prospective multicenter study", Helicobacter, 24, pp.e12592~ (2019)